BAYZED HEALTH (02609) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 1.12 billion, representing a decrease of 5.8% compared to the previous year. The loss attributable to equity shareholders was RMB 12.957 million, narrowing by 3.7% year-on-year. The basic loss per share was RMB 0.01.
The decline in revenue during the period was primarily due to a reduction of RMB 37.4 million in hospital business income, coupled with a decrease of RMB 21.6 million in revenue from the supply of pharmaceuticals, medical equipment, and consumables.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments